CN100350046C - Method for increasing content of astragalus methglycoside through exogenous gene transfer technology - Google Patents
Method for increasing content of astragalus methglycoside through exogenous gene transfer technology Download PDFInfo
- Publication number
- CN100350046C CN100350046C CNB2005100260264A CN200510026026A CN100350046C CN 100350046 C CN100350046 C CN 100350046C CN B2005100260264 A CNB2005100260264 A CN B2005100260264A CN 200510026026 A CN200510026026 A CN 200510026026A CN 100350046 C CN100350046 C CN 100350046C
- Authority
- CN
- China
- Prior art keywords
- vgb
- add
- aseptic
- astragalus
- solution
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 238000000034 method Methods 0.000 title claims abstract description 16
- 108090000623 proteins and genes Proteins 0.000 title claims abstract description 6
- 235000006533 astragalus Nutrition 0.000 title abstract description 67
- 241001061264 Astragalus Species 0.000 title abstract description 47
- 210000004233 talus Anatomy 0.000 title abstract description 47
- 238000012546 transfer Methods 0.000 title abstract description 12
- 238000005516 engineering process Methods 0.000 title abstract description 8
- 241000894006 Bacteria Species 0.000 claims abstract description 33
- 239000013612 plasmid Substances 0.000 claims abstract description 12
- 241000589158 Agrobacterium Species 0.000 claims abstract description 6
- 102000004190 Enzymes Human genes 0.000 claims abstract description 4
- 108090000790 Enzymes Proteins 0.000 claims abstract description 4
- 239000007788 liquid Substances 0.000 claims description 34
- 239000000243 solution Substances 0.000 claims description 27
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 26
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 claims description 22
- 239000006228 supernatant Substances 0.000 claims description 22
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 21
- PHTQWCKDNZKARW-UHFFFAOYSA-N isoamylol Chemical compound CC(C)CCO PHTQWCKDNZKARW-UHFFFAOYSA-N 0.000 claims description 19
- 108020004414 DNA Proteins 0.000 claims description 14
- 239000007787 solid Substances 0.000 claims description 14
- 241000589156 Agrobacterium rhizogenes Species 0.000 claims description 13
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 claims description 9
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 claims description 9
- 238000011081 inoculation Methods 0.000 claims description 9
- 238000006243 chemical reaction Methods 0.000 claims description 7
- 241000588724 Escherichia coli Species 0.000 claims description 6
- 230000029087 digestion Effects 0.000 claims description 6
- 238000002360 preparation method Methods 0.000 claims description 6
- 238000000605 extraction Methods 0.000 claims description 5
- 239000012634 fragment Substances 0.000 claims description 5
- 239000003153 chemical reaction reagent Substances 0.000 claims description 4
- 238000002156 mixing Methods 0.000 claims description 4
- SMDOOINVMJSDPS-UHFFFAOYSA-N Astragaloside Natural products C1=C(O)C(OC)=CC(C2=C(C(=O)C3=C(O)C=C(O)C=C3O2)OC2C(C(OC3C(C(O)C(O)C(CO)O3)O)C(O)C(CO)O2)O)=C1 SMDOOINVMJSDPS-UHFFFAOYSA-N 0.000 claims description 3
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 claims description 3
- QMNWISYXSJWHRY-XWJCTJPOSA-N astragaloside Chemical compound O1[C@H](C(C)(O)C)CC[C@]1(C)[C@@H]1[C@@]2(C)CC[C@]34C[C@]4(CC[C@H](O[C@H]4[C@@H]([C@@H](O)[C@H](O)CO4)O)C4(C)C)C4[C@@H](O[C@H]4[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O4)O)CC3[C@]2(C)C[C@@H]1O QMNWISYXSJWHRY-XWJCTJPOSA-N 0.000 claims description 3
- 230000003115 biocidal effect Effects 0.000 claims description 3
- 238000013461 design Methods 0.000 claims description 3
- 239000011259 mixed solution Substances 0.000 claims description 3
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 claims description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims description 2
- 238000000246 agarose gel electrophoresis Methods 0.000 claims description 2
- 238000000137 annealing Methods 0.000 claims description 2
- GPRBEKHLDVQUJE-VINNURBNSA-N cefotaxime Chemical compound N([C@@H]1C(N2C(=C(COC(C)=O)CS[C@@H]21)C(O)=O)=O)C(=O)/C(=N/OC)C1=CSC(N)=N1 GPRBEKHLDVQUJE-VINNURBNSA-N 0.000 claims description 2
- 239000007795 chemical reaction product Substances 0.000 claims description 2
- 238000001962 electrophoresis Methods 0.000 claims description 2
- 239000008103 glucose Substances 0.000 claims description 2
- 238000000746 purification Methods 0.000 claims description 2
- 230000035939 shock Effects 0.000 claims description 2
- 238000012360 testing method Methods 0.000 claims description 2
- 235000015097 nutrients Nutrition 0.000 claims 12
- 238000011534 incubation Methods 0.000 claims 7
- 238000003752 polymerase chain reaction Methods 0.000 claims 5
- 108700025158 Vitreoscilla hemoglobin Proteins 0.000 claims 4
- 108020004707 nucleic acids Proteins 0.000 claims 4
- 102000039446 nucleic acids Human genes 0.000 claims 4
- 150000007523 nucleic acids Chemical class 0.000 claims 4
- 238000001556 precipitation Methods 0.000 claims 4
- 238000005406 washing Methods 0.000 claims 4
- 102000053602 DNA Human genes 0.000 claims 3
- 238000013016 damping Methods 0.000 claims 3
- 229960004756 ethanol Drugs 0.000 claims 3
- 239000012530 fluid Substances 0.000 claims 3
- 230000000968 intestinal effect Effects 0.000 claims 3
- 108091008146 restriction endonucleases Proteins 0.000 claims 3
- 210000001541 thymus gland Anatomy 0.000 claims 3
- 239000003643 water by type Substances 0.000 claims 3
- 239000009636 Huang Qi Substances 0.000 claims 2
- 238000011156 evaluation Methods 0.000 claims 2
- 238000012216 screening Methods 0.000 claims 2
- 230000001131 transforming effect Effects 0.000 claims 2
- WKVZMKDXJFCMMD-UVWUDEKDSA-L (5ar,8ar,9r)-5-[[(2r,4ar,6r,7r,8r,8as)-7,8-dihydroxy-2-methyl-4,4a,6,7,8,8a-hexahydropyrano[3,2-d][1,3]dioxin-6-yl]oxy]-9-(4-hydroxy-3,5-dimethoxyphenyl)-5a,6,8a,9-tetrahydro-5h-[2]benzofuro[6,5-f][1,3]benzodioxol-8-one;azanide;n,3-bis(2-chloroethyl)-2-ox Chemical compound [NH2-].[NH2-].Cl[Pt+2]Cl.ClCCNP1(=O)OCCCN1CCCl.COC1=C(O)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3C(O[C@H]3[C@@H]([C@@H](O)[C@@H]4O[C@H](C)OC[C@H]4O3)O)[C@@H]3[C@@H]2C(OC3)=O)=C1 WKVZMKDXJFCMMD-UVWUDEKDSA-L 0.000 claims 1
- NYHBQMYGNKIUIF-UUOKFMHZSA-N Guanosine Chemical compound C1=NC=2C(=O)NC(N)=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O NYHBQMYGNKIUIF-UUOKFMHZSA-N 0.000 claims 1
- 102000003960 Ligases Human genes 0.000 claims 1
- 108090000364 Ligases Proteins 0.000 claims 1
- 240000004808 Saccharomyces cerevisiae Species 0.000 claims 1
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 claims 1
- 239000004141 Sodium laurylsulphate Substances 0.000 claims 1
- 230000003213 activating effect Effects 0.000 claims 1
- 229960004261 cefotaxime Drugs 0.000 claims 1
- 230000004087 circulation Effects 0.000 claims 1
- 230000001351 cycling effect Effects 0.000 claims 1
- 230000009849 deactivation Effects 0.000 claims 1
- 229960000935 dehydrated alcohol Drugs 0.000 claims 1
- 238000003780 insertion Methods 0.000 claims 1
- 230000037431 insertion Effects 0.000 claims 1
- 230000013011 mating Effects 0.000 claims 1
- 239000002342 ribonucleoside Substances 0.000 claims 1
- 235000019333 sodium laurylsulphate Nutrition 0.000 claims 1
- 238000009423 ventilation Methods 0.000 claims 1
- 238000003805 vibration mixing Methods 0.000 claims 1
- 101150112266 vgb gene Proteins 0.000 abstract description 48
- 230000009261 transgenic effect Effects 0.000 abstract description 42
- 108010054147 Hemoglobins Proteins 0.000 abstract description 4
- 230000014509 gene expression Effects 0.000 abstract description 3
- 238000005520 cutting process Methods 0.000 abstract description 2
- 238000005259 measurement Methods 0.000 abstract description 2
- 206010061592 cardiac fibrillation Diseases 0.000 abstract 1
- 230000002600 fibrillogenic effect Effects 0.000 abstract 1
- QMNWISYXSJWHRY-YLNUDOOFSA-N astragaloside IV Chemical compound O1[C@H](C(C)(O)C)CC[C@]1(C)[C@@H]1[C@@]2(C)CC[C@]34C[C@]4(CC[C@H](O[C@H]4[C@@H]([C@@H](O)[C@H](O)CO4)O)C4(C)C)[C@H]4[C@@H](O[C@H]4[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O4)O)C[C@H]3[C@]2(C)C[C@@H]1O QMNWISYXSJWHRY-YLNUDOOFSA-N 0.000 description 43
- QMNWISYXSJWHRY-BCBPIKMJSA-N astragaloside IV Natural products CC(C)(O)[C@@H]1CC[C@@](C)(O1)[C@H]2[C@@H](O)C[C@@]3(C)[C@@H]4C[C@H](O[C@@H]5O[C@H](CO)[C@H](O)[C@@H](O)[C@H]5O)[C@H]6C(C)(C)[C@H](CC[C@@]67C[C@@]47CC[C@]23C)O[C@@H]8OC[C@@H](O)[C@H](O)[C@H]8O QMNWISYXSJWHRY-BCBPIKMJSA-N 0.000 description 43
- PFKIBRPYVNVMRU-UHFFFAOYSA-N cyclosieversioside F Natural products CC(C)(O)C1COC(C)(C1)C2C(O)CC3(C)C4CC(OC5OC(CO)C(O)C(O)C5O)C6C(C)(C)C(CCC67CC47CCC23C)OC8OCC(O)C(O)C8O PFKIBRPYVNVMRU-UHFFFAOYSA-N 0.000 description 43
- 241000045403 Astragalus propinquus Species 0.000 description 21
- 239000002609 medium Substances 0.000 description 20
- 239000000203 mixture Substances 0.000 description 13
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 9
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical class CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 description 7
- 229930027917 kanamycin Natural products 0.000 description 7
- 229960000318 kanamycin Drugs 0.000 description 7
- SBUJHOSQTJFQJX-NOAMYHISSA-N kanamycin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CN)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](N)[C@H](O)[C@@H](CO)O2)O)[C@H](N)C[C@@H]1N SBUJHOSQTJFQJX-NOAMYHISSA-N 0.000 description 7
- 229930182823 kanamycin A Natural products 0.000 description 7
- 238000004519 manufacturing process Methods 0.000 description 7
- 239000000463 material Substances 0.000 description 7
- 239000002244 precipitate Substances 0.000 description 7
- 241000196324 Embryophyta Species 0.000 description 6
- 239000003814 drug Substances 0.000 description 6
- JQXXHWHPUNPDRT-WLSIYKJHSA-N rifampicin Chemical compound O([C@](C1=O)(C)O/C=C/[C@@H]([C@H]([C@@H](OC(C)=O)[C@H](C)[C@H](O)[C@H](C)[C@@H](O)[C@@H](C)\C=C\C=C(C)/C(=O)NC=2C(O)=C3C([O-])=C4C)C)OC)C4=C1C3=C(O)C=2\C=N\N1CC[NH+](C)CC1 JQXXHWHPUNPDRT-WLSIYKJHSA-N 0.000 description 6
- 229960001225 rifampicin Drugs 0.000 description 6
- 239000013642 negative control Substances 0.000 description 5
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 4
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 4
- 108700019146 Transgenes Proteins 0.000 description 4
- 238000010586 diagram Methods 0.000 description 4
- 239000013558 reference substance Substances 0.000 description 4
- 102100031780 Endonuclease Human genes 0.000 description 3
- 241000208125 Nicotiana Species 0.000 description 3
- 235000002637 Nicotiana tabacum Nutrition 0.000 description 3
- 238000001514 detection method Methods 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 238000000105 evaporative light scattering detection Methods 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 239000000706 filtrate Substances 0.000 description 3
- 239000003550 marker Substances 0.000 description 3
- 239000000843 powder Substances 0.000 description 3
- 239000008223 sterile water Substances 0.000 description 3
- 239000012085 test solution Substances 0.000 description 3
- 230000009466 transformation Effects 0.000 description 3
- 239000013598 vector Substances 0.000 description 3
- LZZYPRNAOMGNLH-UHFFFAOYSA-M Cetrimonium bromide Chemical compound [Br-].CCCCCCCCCCCCCCCC[N+](C)(C)C LZZYPRNAOMGNLH-UHFFFAOYSA-M 0.000 description 2
- 241000620209 Escherichia coli DH5[alpha] Species 0.000 description 2
- 102000001554 Hemoglobins Human genes 0.000 description 2
- NTYJJOPFIAHURM-UHFFFAOYSA-N Histamine Chemical compound NCCC1=CN=CN1 NTYJJOPFIAHURM-UHFFFAOYSA-N 0.000 description 2
- 208000004880 Polyuria Diseases 0.000 description 2
- 108010092799 RNA-directed DNA polymerase Proteins 0.000 description 2
- 241000208832 Viburnum Species 0.000 description 2
- 235000019013 Viburnum opulus Nutrition 0.000 description 2
- 206010047642 Vitiligo Diseases 0.000 description 2
- 241000863000 Vitreoscilla Species 0.000 description 2
- OJOBTAOGJIWAGB-UHFFFAOYSA-N acetosyringone Chemical compound COC1=CC(C(C)=O)=CC(OC)=C1O OJOBTAOGJIWAGB-UHFFFAOYSA-N 0.000 description 2
- 230000004913 activation Effects 0.000 description 2
- 239000004480 active ingredient Substances 0.000 description 2
- 239000003242 anti bacterial agent Substances 0.000 description 2
- 229940088710 antibiotic agent Drugs 0.000 description 2
- 230000001580 bacterial effect Effects 0.000 description 2
- 239000002299 complementary DNA Substances 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 230000035619 diuresis Effects 0.000 description 2
- 239000013604 expression vector Substances 0.000 description 2
- 238000010353 genetic engineering Methods 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- 241000411851 herbal medicine Species 0.000 description 2
- 238000004128 high performance liquid chromatography Methods 0.000 description 2
- 210000004276 hyalin Anatomy 0.000 description 2
- 238000009396 hybridization Methods 0.000 description 2
- 239000012982 microporous membrane Substances 0.000 description 2
- 229910052757 nitrogen Inorganic materials 0.000 description 2
- 238000011017 operating method Methods 0.000 description 2
- 239000008188 pellet Substances 0.000 description 2
- 230000035699 permeability Effects 0.000 description 2
- 239000013641 positive control Substances 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 238000011084 recovery Methods 0.000 description 2
- 238000010839 reverse transcription Methods 0.000 description 2
- 238000003757 reverse transcription PCR Methods 0.000 description 2
- DGVVWUTYPXICAM-UHFFFAOYSA-N β‐Mercaptoethanol Chemical compound OCCS DGVVWUTYPXICAM-UHFFFAOYSA-N 0.000 description 2
- SNICXCGAKADSCV-JTQLQIEISA-N (-)-Nicotine Chemical compound CN1CCC[C@H]1C1=CC=CN=C1 SNICXCGAKADSCV-JTQLQIEISA-N 0.000 description 1
- 240000007124 Brassica oleracea Species 0.000 description 1
- 235000003899 Brassica oleracea var acephala Nutrition 0.000 description 1
- 235000011301 Brassica oleracea var capitata Nutrition 0.000 description 1
- 235000001169 Brassica oleracea var oleracea Nutrition 0.000 description 1
- 241000700199 Cavia porcellus Species 0.000 description 1
- 102000008186 Collagen Human genes 0.000 description 1
- 108010035532 Collagen Proteins 0.000 description 1
- 102000012410 DNA Ligases Human genes 0.000 description 1
- 108010061982 DNA Ligases Proteins 0.000 description 1
- 108010042407 Endonucleases Proteins 0.000 description 1
- 241000588698 Erwinia Species 0.000 description 1
- 206010021143 Hypoxia Diseases 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 206010028594 Myocardial fibrosis Diseases 0.000 description 1
- 208000009525 Myocarditis Diseases 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 241000589516 Pseudomonas Species 0.000 description 1
- 238000002123 RNA extraction Methods 0.000 description 1
- 102000006382 Ribonucleases Human genes 0.000 description 1
- 108010083644 Ribonucleases Proteins 0.000 description 1
- 241000187747 Streptomyces Species 0.000 description 1
- PBCJIPOGFJYBJE-UHFFFAOYSA-N acetonitrile;hydrate Chemical compound O.CC#N PBCJIPOGFJYBJE-UHFFFAOYSA-N 0.000 description 1
- 241001148470 aerobic bacillus Species 0.000 description 1
- 238000007605 air drying Methods 0.000 description 1
- 125000003275 alpha amino acid group Chemical group 0.000 description 1
- 230000002424 anti-apoptotic effect Effects 0.000 description 1
- 210000000709 aorta Anatomy 0.000 description 1
- 230000006907 apoptotic process Effects 0.000 description 1
- 229940107666 astragalus root Drugs 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 230000008499 blood brain barrier function Effects 0.000 description 1
- 210000001218 blood-brain barrier Anatomy 0.000 description 1
- 210000005013 brain tissue Anatomy 0.000 description 1
- 239000012159 carrier gas Substances 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 239000000919 ceramic Substances 0.000 description 1
- 230000002490 cerebral effect Effects 0.000 description 1
- 229930002875 chlorophyll Natural products 0.000 description 1
- 235000019804 chlorophyll Nutrition 0.000 description 1
- ATNHDLDRLWWWCB-AENOIHSZSA-M chlorophyll a Chemical compound C1([C@@H](C(=O)OC)C(=O)C2=C3C)=C2N2C3=CC(C(CC)=C3C)=[N+]4C3=CC3=C(C=C)C(C)=C5N3[Mg-2]42[N+]2=C1[C@@H](CCC(=O)OC\C=C(/C)CCC[C@H](C)CCC[C@H](C)CCCC(C)C)[C@H](C)C2=C5 ATNHDLDRLWWWCB-AENOIHSZSA-M 0.000 description 1
- 229940088530 claforan Drugs 0.000 description 1
- 238000013373 clone screening Methods 0.000 description 1
- 229920001436 collagen Polymers 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 230000008602 contraction Effects 0.000 description 1
- 238000012258 culturing Methods 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 239000008367 deionised water Substances 0.000 description 1
- 229910021641 deionized water Inorganic materials 0.000 description 1
- 238000004925 denaturation Methods 0.000 description 1
- 230000036425 denaturation Effects 0.000 description 1
- 238000001784 detoxification Methods 0.000 description 1
- 230000002526 effect on cardiovascular system Effects 0.000 description 1
- 238000001704 evaporation Methods 0.000 description 1
- 230000008020 evaporation Effects 0.000 description 1
- 238000010812 external standard method Methods 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 238000001502 gel electrophoresis Methods 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- YQOKLYTXVFAUCW-UHFFFAOYSA-N guanidine;isothiocyanic acid Chemical compound N=C=S.NC(N)=N YQOKLYTXVFAUCW-UHFFFAOYSA-N 0.000 description 1
- 229910001385 heavy metal Inorganic materials 0.000 description 1
- 229960001340 histamine Drugs 0.000 description 1
- 238000000265 homogenisation Methods 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 230000007954 hypoxia Effects 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 238000009776 industrial production Methods 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 230000037353 metabolic pathway Effects 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 238000001823 molecular biology technique Methods 0.000 description 1
- 239000004570 mortar (masonry) Substances 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 230000002107 myocardial effect Effects 0.000 description 1
- 238000002663 nebulization Methods 0.000 description 1
- 229960002715 nicotine Drugs 0.000 description 1
- SNICXCGAKADSCV-UHFFFAOYSA-N nicotine Natural products CN1CCCC1C1=CC=CN=C1 SNICXCGAKADSCV-UHFFFAOYSA-N 0.000 description 1
- 238000009377 nuclear transmutation Methods 0.000 description 1
- 230000002669 organ and tissue protective effect Effects 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 239000000575 pesticide Substances 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 150000002989 phenols Chemical class 0.000 description 1
- 238000012257 pre-denaturation Methods 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 239000003223 protective agent Substances 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 230000008844 regulatory mechanism Effects 0.000 description 1
- 210000005245 right atrium Anatomy 0.000 description 1
- 239000001509 sodium citrate Substances 0.000 description 1
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 1
- 229940079862 sodium lauryl sarcosinate Drugs 0.000 description 1
- ADWNFGORSPBALY-UHFFFAOYSA-M sodium;2-[dodecyl(methyl)amino]acetate Chemical compound [Na+].CCCCCCCCCCCCN(C)CC([O-])=O ADWNFGORSPBALY-UHFFFAOYSA-M 0.000 description 1
- 238000002798 spectrophotometry method Methods 0.000 description 1
- 230000002269 spontaneous effect Effects 0.000 description 1
- 238000013112 stability test Methods 0.000 description 1
- 238000005728 strengthening Methods 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 230000002194 synthesizing effect Effects 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 230000014616 translation Effects 0.000 description 1
- 206010047470 viral myocarditis Diseases 0.000 description 1
Images
Landscapes
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Abstract
Description
技术领域:Technical field:
本发明属于中药技术领域。具体涉及一种转外源基因技术提高黄芪甲苷含量。The invention belongs to the technical field of traditional Chinese medicine. Specifically, it relates to a technology of exogenous gene transfer to increase the content of astragaloside IV.
背景技术:Background technique:
黄芪(Astragalus membranaceus或A.mongholicus)是我国重要的中药材品种之一,具有补益固表、利尿排毒、生肌敛疮、利水消肿作用,是许多中药复方、成药和保健品的主要成分。随着人们日益增长的保健观念的强化,黄芪的需求量将会逐年增加;但目前黄芪的野生资源逐年减少,栽培品种品质下降且面临农药污染及重金属残留等问题的困扰,给临床和成药加工、出口带来一定的困难。因而应用现代生物技术提高黄芪的产量,改善其品质,探索工业化生产的可行途径对黄芪的生产具有重要的意义。黄芪甲苷是中国药典规定的含测指标,如果能寻找到高黄芪甲苷含量的人工黄芪产品,将具有良好的开发和应用前景。Astragalus membranaceus or A.mongholicus is one of the important varieties of Chinese herbal medicines in my country. It has the functions of tonifying and solidifying the exterior, diuresis and detoxification, promoting muscle and reducing sores, diuresis and detumescence, and is the main component of many traditional Chinese medicine compounds, patent medicines and health care products. With the strengthening of people's growing health care concept, the demand for Astragalus membranaceus will increase year by year; but at present, the wild resources of Astragalus membranaceus are decreasing year by year, the quality of cultivated varieties is declining, and they are facing problems such as pesticide pollution and heavy metal residues. , Export brings certain difficulties. Therefore, the application of modern biotechnology to increase the output of Astragalus membranaceus, improve its quality, and explore feasible ways of industrial production are of great significance to the production of Astragalus membranaceus. Astragaloside Ⅳ is the content detection index stipulated in the Chinese Pharmacopoeia. If an artificial astragaloside product with high content of astragaloside Ⅳ can be found, it will have a good development and application prospect.
八十年代以来,以全蛋白肽谱、同工酶谱、氨基酸序列分析、酶免疫测定以及核酸分析技术为主要内容的分子生物学技术,特别是基因工程技术已成功地应用于中药生产、品质鉴定改良中,为中药生产注入了新的活力。以发根农杆菌(Agrobacteriumrhizogenesis)诱导生成的毛状根具有生长迅速,不需要添加外源激素,拥有亲本植株的代谢途径,遗传稳定,易于扩大培养等优点,如果再能增加其有效成分含量,将有利于实现工业化生产。Since the 1980s, molecular biology techniques, especially genetic engineering techniques, have been successfully applied to the production, quality and The improvement of identification has injected new vitality into the production of traditional Chinese medicine. The hairy roots induced by Agrobacterium rhizogenesis have the advantages of rapid growth, no need to add exogenous hormones, metabolic pathways of parent plants, stable genetics, and easy expansion and cultivation. If the content of active ingredients can be increased, It will be beneficial to realize industrialized production.
透明颤菌血红蛋白(Vitreoscilla Haemoglobin,简称VHb)是透明颤菌属(Vitreoscitlasp.)中产生的一种可溶性血红蛋白,这种血红蛋白能在贫氧条件下被大量诱导合成,使透明颤菌在微氧条件下能够很好的生存。科学家们根据已报道的VHb氨基酸序列,克隆了透明颤菌血红蛋白基因(Vitreoscilla Haemoglobin gene,简称vgb gene)。由于vgb基因调控机制在专性和兼性耗氧菌中十分保守,它在多种微生物中都获得了表达,如大肠杆菌、假单胞杆菌、链霉菌、欧文氏菌等;该表达可以提高酶产量、总蛋白产量和抗生素的产量。目前,vgb基因在植物领域应用较少,且多集中在农业领域。如瑞典和瑞士科学家将透明颤菌血红蛋白首次应用到植物领域,他们将VHb在烟草中表达,得到转vgb基因烟草,该转vgb基因烟草的种子萌发提前,生长快,植株的叶绿素含量增加;生物碱含量也发生变化,尼古丁含量明显增加,而新烟碱的含量却减少。另外,转vgb基因卷心菜能够增加抗涝能力。但迄今为止,未见该技术在中草药中的应用。我国的中药材大都以根茎入药,由于根部是处于地面以下,获得氧气较地面以上部分要困难得多,所以更需要解决耐缺氧问题。Vitreoscilla Haemoglobin (VHb for short) is a kind of soluble hemoglobin produced in Vitreoscitlas (Vitreoscitlasp.). can survive well. Scientists cloned the Vitreoscilla Haemoglobin gene (Vgb gene for short) based on the reported VHb amino acid sequence. Because the vgb gene regulation mechanism is very conservative in obligate and facultative aerobic bacteria, it has been expressed in a variety of microorganisms, such as Escherichia coli, Pseudomonas, Streptomyces, Erwinia, etc.; this expression can improve Enzyme production, total protein production and antibiotic production. At present, the vgb gene is rarely used in the field of plants, and most of them are concentrated in the field of agriculture. For example, scientists from Sweden and Switzerland applied Vitiligo hyaline hemoglobin to the plant field for the first time. They expressed VHb in tobacco and obtained transgenic tobacco. The seeds of the transgenic tobacco germinated earlier, grew faster, and the chlorophyll content of the plant increased; biological Alkaline levels also changed, with significantly more nicotine and less neonicotinoid. In addition, the transgenic vgb cabbage can increase the waterlogging resistance. But so far, there is no application of this technology in Chinese herbal medicine. Most Chinese medicinal materials in my country use rhizomes as medicines. Because the roots are below the ground, it is much more difficult to obtain oxygen than the parts above the ground, so it is more necessary to solve the problem of hypoxia resistance.
发明内容:Invention content:
本发明所要解决的技术问题在于把毛状根技术与基因工程相结合,获得生长周期短、产量高、黄芪甲苷含量高的转vgb基因黄芪毛状根。The technical problem to be solved by the present invention is to combine the hairy root technology with genetic engineering to obtain the vgb gene transgenic astragalus hairy root with short growth period, high yield and high content of astragaloside IV.
本发明提供了一种转外源基因技术提高黄芪甲苷含量的方法。The invention provides a method for improving the content of astragaloside IV through exogenous gene transfer technology.
本发明将透明颤菌血红蛋白基因经改造后,采用酶切结合PCR技术,将vgb基因插入质粒pBI121,获得以35s-CaMV强启动子为启动元件的中间表达载体pBI121-vgb,并转入大肠杆菌DH5α。采用三亲杂交法(pRK2013、DH5α和LBA9402),获得转vgb基因的发根农杆菌LBA9402-vgb。利用LBA9402-vgb侵染黄芪无菌苗,并进行分子鉴定,证明是转vgb基因黄芪毛状根。测定转vgb基因黄芪毛状根生长量和黄芪甲苷的含量,结果表明转vgb基因黄芪毛状根中黄芪甲苷含量高于未转基因黄芪毛状根含量5倍,高于商品药材膜荚黄芪含量10倍以上;同期相比转vgb基因黄芪毛状根干重比未转基因黄芪毛状根增加13%~25%。In the present invention, after the hemoglobin gene of Vitiligo hyaline is transformed, the vgb gene is inserted into the plasmid pBI121 by enzyme cutting and PCR technology, and the intermediate expression vector pBI121-vgb with the 35s-CaMV strong promoter as the promoter element is obtained, and transformed into Escherichia coli DH5α. Agrobacterium rhizogenes LBA9402-vgb transmuted with vgb gene was obtained by triparental hybridization method (pRK2013, DH5α and LBA9402). LBA9402-vgb was used to infect Astragalus aseptic seedlings, and the molecular identification proved that the transgenic vgb gene Astragalus hairy roots. The growth of transgenic vgb gene Astragalus hairy roots and the content of astragaloside IV were measured, and the results showed that the content of astragaloside IV in transgenic vgb gene Astragalus hairy roots was 5 times higher than that of non-transgenic Astragalus hairy roots, and higher than that of the commercial medicinal material Astragalus membranaceus The content is more than 10 times; compared with the same period, the dry weight of the hairy root of astragalus with vgb gene is increased by 13% to 25% compared with that of the hairy root of astragalus without transgene.
通过本发明技术得到的转vgb基因黄芪毛状根可以增加产量和有效成分黄芪甲苷的含量。同期相比,转vgb基因黄芪毛状根干重比未转基因黄芪毛状根增加13%~25%;其中株系36与52的黄芪甲苷含量分别为20.674mg/g和20.999mg/g,是未转基因黄芪毛状根(黄芪甲苷含量为3.334mg/g)的6.2倍,是山西产膜荚黄芪(黄芪甲苷含量为1.774mg/g)的11.6倍。由于不同产地药材的黄芪甲苷含量有所不同,参考中国药典[1]的规定:黄芪甲苷不得少于0.4mg/g,以及上海市中药标准化中心收集测定的不同来源商品黄芪中黄芪甲苷的含量:0.5mg/g~1.9mg/g,可以推断转vgb基因黄芪毛状根具有良好的合成黄芪甲苷的能力。The transgenic hairy root of astragalus membranaceus obtained by the technique of the invention can increase the yield and the content of the active ingredient astragaloside IV. Compared with the same period, the dry weight of hairy roots of Astragalus transgenic with vgb gene increased by 13%-25% compared with that of non-transgenic Astragalus hairy roots; the contents of astragaloside IV in lines 36 and 52 were 20.674mg/g and 20.999mg/g respectively, It is 6.2 times that of non-transgenic Astragalus hairy root (the content of astragaloside IV is 3.334mg/g), and it is 11.6 times that of Shanxi membranous viburnum (the content of astragaloside IV is 1.774mg/g). As the content of astragaloside IV in medicinal materials from different origins is different, refer to the regulations of the Chinese Pharmacopoeia [1]: astragaloside IV should not be less than 0.4mg/g, and the astragaloside IV in Astragalus membranaceus from different sources collected and determined by Shanghai Traditional Chinese Medicine Standardization Center Content: 0.5mg/g~1.9mg/g, it can be inferred that the hairy root of Astragalus transgenic vgb gene has a good ability to synthesize astragaloside IV.
黄芪甲苷是中国药典规定的含测指标,具有良好的心脑血管药理活性。黄芪甲苷可以提高心肌炎小鼠生存率,减少胶原合成和心肌细胞凋亡,安全有效;其抗凋亡效应对延缓或逆转病毒性心肌炎心肌纤维化起重要作用。研究证明黄芪甲苷可以降低血脑屏障的通透性,是一种脑组织保护剂,黄芪甲苷对KCl和CaCl2所致的离体兔主动脉环收缩和对离体豚鼠右心房自发性节律有抑制作用同时,由组胺引起的脑微血管通透性增加能够被黄芪甲苷抑制。这些均显示了黄芪甲苷具有很好的市场应用前景,本发明通过转vgb基因获得的转基因黄芪毛状根不仅能增加产量,同时还能大幅度提高黄芪甲苷含量,可以为黄芪甲苷工业化生产提供优质原材料,具有良好的开发前景。Astragaloside IV is the content detection index stipulated in the Chinese Pharmacopoeia, and has good cardiovascular and cerebrovascular pharmacological activities. Astragaloside IV can improve the survival rate of myocarditis mice, reduce collagen synthesis and myocardial cell apoptosis, and is safe and effective; its anti-apoptotic effect plays an important role in delaying or reversing myocardial fibrosis in viral myocarditis. Studies have proved that astragaloside IV can reduce the permeability of the blood-brain barrier, and is a brain tissue protective agent. Astragaloside IV can reduce the contraction of the isolated rabbit aorta ring caused by KCl and CaCl 2 and the spontaneous right atrium of the isolated guinea pig. At the same time, the increase of cerebral microvascular permeability caused by histamine can be inhibited by astragaloside IV. These all show that astragaloside IV has a good market application prospect. The transgenic astragaloside hairy root obtained by the transgenic vgb gene of the present invention can not only increase the yield, but also greatly increase the content of astragaloside IV, which can be used for the industrialization of astragaloside IV. Production provides high-quality raw materials and has good development prospects.
附图说明:Description of drawings:
图1:质粒pBI 121-vgb、发根农杆菌LBA9402-vgb PCR鉴定图。Figure 1: PCR identification diagram of plasmid pBI 121-vgb and Agrobacterium rhizogenes LBA9402-vgb.
图2:转vgb基因黄芪毛状根PCR鉴定图。Figure 2: PCR identification diagram of hairy root of Astragalus membranaceus transgenic with vgb gene.
图3:转vgb基因黄芪毛状根RT-PCR鉴定图。Fig. 3: RT-PCR identification diagram of hairy root of Astragalus membranaceus transgenic with vgb gene.
图4:HPLC-ELSD法测定黄芪甲苷的含量;Figure 4: Determination of the content of astragaloside IV by HPLC-ELSD;
图4.1:黄芪甲苷结构图;Figure 4.1: Structural diagram of astragaloside IV;
图4.2:黄芪甲苷标准品HPLC图;Figure 4.2: HPLC chart of astragaloside IV standard;
图4.3:样品(转vgb基因黄芪毛状根VHb52)黄芪甲苷测定HPLC图。Figure 4.3: HPLC chart of astragaloside IV determination of the sample (transformed vgb gene Astragalus hairy root VHb52).
实施例1Example 1
1)质粒pBI 121的提取1) Extraction of plasmid pBI 121
反应试剂的配制:LB液体培养基;溶液1(50mM葡萄糖,25mM Tris-HCl,10mMEDTA,pH 8.0);溶液2(0.2M NaOH,1%SDS);溶液3(5M KAc 60ml,HAc 11.5ml,H2O 28.5ml);酚∶氯仿∶异戊醇(25∶24∶1)混合液;RNA酶(20μg/ml);无水乙醇;70%乙醇。Preparation of reaction reagents: LB liquid medium; solution 1 (50mM glucose, 25mM Tris-HCl, 10mM EDTA, pH 8.0); solution 2 (0.2M NaOH, 1% SDS); solution 3 (5M KAc 60ml, HAc 11.5ml, H 2 O 28.5ml); phenol:chloroform:isoamyl alcohol (25:24:1) mixture; RNase (20 μg/ml); absolute ethanol; 70% ethanol.
操作程序:取2ml含抗生素的LB液体培养基,加入15ml的通气良好的试管中,然后从转化平板上挑一单菌落,37℃,300rpm,培养过夜;取1.5ml培养物,4℃,12000rpm,离心0.5min,倒去上清液,沉淀尽可能干燥;加100μl溶液1重新悬浮细菌,剧烈震荡;加200μl溶液2,盖紧盖子,快速颠倒混匀,置冰上;加150μl冰预冷的溶液3,盖紧盖子,颠倒混匀,置冰上3~5min;12000rpm,4℃,离心5min,上清转移;加等体积的酚∶氯仿∶异戊醇混合液,振荡混匀,4℃,12000rpm,离心10min,转移上清液;在上清中加2倍体积乙醇,室温放置2分钟;12000rpm,4℃,离心5min;弃上清,沉淀;加1ml 70%乙醇洗涤,4℃,12000rpm,离心10min,沉淀空气干燥10min;加50μl含胰RNA酶的ddH2O溶解DNA,储存于-20℃待用。Operating procedures: Take 2ml of LB liquid medium containing antibiotics, add it to a 15ml well-ventilated test tube, then pick a single colony from the transformation plate, culture at 37°C, 300rpm overnight; take 1.5ml of culture, 4°C, 12000rpm , centrifuge for 0.5min, discard the supernatant, and make the pellet as dry as possible; add 100μl solution 1 to resuspend the bacteria, and shake vigorously; add
2)双酶切(XbaI-SacI)2) Double digestion (XbaI-SacI)
10×双酶切缓冲液10μl,XbaI(10U/μl)3μl,SacI(10U/μl)3μl,DNA 10μg,ddH2O10 μl of 10× double digestion buffer, 3 μl of XbaI (10U/μl), 3 μl of SacI (10U/μl), 10 μg of DNA, ddH 2 O
37℃水浴1hr,取出75℃灭活内切酶;取5μl电泳鉴定,其余部分酚∶氯仿∶异戊醇(25∶24∶1)萃取纯化后,加1/10体积的3M NaAc,2体积的乙醇沉淀DNA;静置10min后,12000rpm,4℃,离心10min,沉淀用70%乙醇洗涤两次后晾干约10min,加适量的无菌水溶解,进行连接。Water bath at 37°C for 1 hour, remove endonuclease at 75°C; take 5 μl for identification by electrophoresis, extract and purify the rest with phenol:chloroform:isoamyl alcohol (25:24:1), add 1/10 volume of 3M NaAc, add 2 volumes Precipitate DNA with ethanol; let stand for 10 minutes, centrifuge at 12000rpm, 4°C for 10 minutes, wash the precipitate twice with 70% ethanol, dry for about 10 minutes, add appropriate amount of sterile water to dissolve, and connect.
3)感受态细菌的制备3) Preparation of Competent Bacteria
从-70℃低温冰箱取出大肠杆菌DH5α,接种于LB平板,37℃培养过夜进行活化。从活化平皿上挑取单菌落,接入5ml不含抗生素的LB液体培养基中,37℃振摇培养过夜(250rpm)。次日按1%(V/V)比例转入新鲜的LB液体培养基中,37℃振摇培养至OD600=0.3(0.3~0.6也可)。在无菌条件下,将50~100ml培养液转入两个预冷的无菌离心管(Falcon 2070管)中,冰上静置10min。4℃,4000rpm离心10min,弃去上清液。倒置流尽培养液。加10ml预冷的0.1M CaCl2溶液,重悬浮细菌,冰浴30min。4℃,4000rpm离心10min,弃去上清液。加2ml预冷的0.1M CaCl2溶液,重悬浮细菌,即为感受态细胞。Escherichia coli DH5α was taken out from the -70°C low-temperature refrigerator, inoculated on LB plates, and cultured overnight at 37°C for activation. Pick a single colony from the activation plate, insert it into 5 ml of LB liquid medium without antibiotics, and cultivate overnight at 37° C. with shaking (250 rpm). The next day, they were transferred to fresh LB liquid medium at a ratio of 1% (V/V), and cultured with shaking at 37°C until OD 600 =0.3 (0.3-0.6 is also acceptable). Under sterile conditions, transfer 50-100ml of the culture solution into two pre-cooled sterile centrifuge tubes (Falcon 2070 tubes), and let stand on ice for 10 minutes. Centrifuge at 4000rpm for 10min at 4°C and discard the supernatant. Inverted to drain the culture medium. Add 10ml of pre-cooled 0.1M CaCl 2 solution, resuspend the bacteria, and ice-bath for 30min. Centrifuge at 4000rpm for 10min at 4°C and discard the supernatant. Add 2ml of pre-cooled 0.1M CaCl 2 solution to resuspend the bacteria, which are competent cells.
4)引物设计4) Primer design
根据已经发表的vgb基因序列设计了如下的引物,预期片断长度451bp。The following primers were designed according to the published vgb gene sequence, and the expected fragment length was 451bp.
正向:5′-AAG GAT CCA TGT TAG ACC AGC AAA CC-3′Forward: 5′-AAG GAT CCA TGT TAG ACC AGC AAA CC-3′
反向:5′-ACAAGC TTATTCAAC CGC TTG AGC-3′Reverse: 5′-ACAAGC TTATTCAAC CGC TTG AGC-3′
5)质粒与插入片段的连接5) Ligation of plasmid and insert
10×连接缓冲液1μl,公开发表的vgb基因经双酶切纯化得到的DNA片断,插入片段和载体pBI 121的摩尔比例约为2∶1,T4 DNA连接酶(5U/μl)1μl,ddH2O,16℃水浴过夜。连接液用于转化。1 μl of 10× ligation buffer, the DNA fragment obtained by double digestion and purification of the published vgb gene, the molar ratio of the insert fragment and the vector pBI 121 is about 2:1, T4 DNA ligase (5U/μl) 1 μl, ddH 2 O, 16°C water bath overnight. The linking solution was used for transformation.
6)PCR反应6) PCR reaction
模板1μl,引物1(5μM)2μl,引物2(5μM)2μl,10×缓冲液2μl,MgCl2(25mM)1.6μl,dNTPs(10mM)0.5μl,Taq(3U/μl)0.3μl,ddH2OTemplate 1 μl, primer 1 (5 μM) 2 μl, primer 2 (5 μM) 2 μl, 10×
PCR循环条件:94℃预变性5min;94℃变性30sec,55℃退火30sec,72℃延伸30sec,30个循环;最后72℃延伸5min。反应完毕后,取4μl反应产物上样于1.0%琼脂糖凝胶电泳。PCR cycle conditions: pre-denaturation at 94°C for 5 min; denaturation at 94°C for 30 sec, annealing at 55°C for 30 sec, extension at 72°C for 30 sec, 30 cycles; final extension at 72°C for 5 min. After the reaction was completed, 4 μl of the reaction product was loaded on 1.0% agarose gel electrophoresis.
6)转化与克隆筛选6) Transformation and clone screening
取100μl感受态细胞,加4μl步骤5)得到的连接液,冰浴30min后,42℃热激1.5min,冰上冷却1~2min;加SOC培养基800μl,于37℃,180rpm培养1hr;取培养物100μl铺于含50μg/ml卡那霉素的LB平板,37℃恒温培养箱过夜培养,PCR方法筛选携带中间载体pBI121-vgb的大肠杆菌。图中M:100bp DNA Marker;1:阴性对照/质粒pBI 121;2:含vgb基因表达载体pBI 121-vgb的大肠杆菌;3:含vgb基因发根农杆菌LBA9402-vgbTake 100 μl of competent cells, add 4 μl of the connection solution obtained in step 5), after 30 minutes in ice bath, heat shock at 42°C for 1.5 minutes, and cool on ice for 1-2 minutes; add 800 μl of SOC medium, and incubate at 37°C, 180rpm for 1 hr; 100 μl of the culture was spread on an LB plate containing 50 μg/ml kanamycin, cultivated overnight in a constant temperature incubator at 37°C, and E. coli carrying the intermediate vector pBI121-vgb was screened by PCR. In the figure M: 100bp DNA Marker; 1: Negative control/plasmid pBI 121; 2: Escherichia coli containing vgb gene expression vector pBI 121-vgb; 3: Agrobacterium rhizogenes LBA9402-vgb containing vgb gene
7)三亲杂交法将vgb基因转入发根农杆菌7) Three-parent hybridization method to transfer vgb gene into Agrobacterium rhizogenes
接种发根农杆菌LBA9402在含有100μg/ml利福平的YMB固体培养基上,28℃培养至单菌落长出。挑单菌落接种于加100μg/ml利福平的YMB液体培养基,28℃,250rpm,培养约40hr。按1%的接种比例将农杆菌接种于YMB液体培养基中,28℃,250rpm培养至OD600为0.5。接种含有协助质粒的大肠杆菌pRK2013以及携带中间载体pBI121-vgb的大肠杆菌于含50μg/ml卡那霉素固体LB培养基上,37℃,300rpm培养过夜,当单菌落长出后,分别挑单菌接种于含50μg/ml卡那霉素液体LB培养基中,37℃,300rpm培养过夜。按1%的接种比例将协助菌和含中间载体的细菌接种于LB液体培养基中,37℃,300rpm培养至OD600为0.5。将三种菌等体积混匀后,取50μl接种于直径2cm的无菌滤纸上置于YMB固体培养基上,25℃培养一天。用适量无菌水冲洗滤纸片,收集洗出的菌液,均匀涂布于含有100μg/ml利福平,50μg/ml卡那霉素的YMB固体培养基上,25℃培养约四天后出现单菌落。挑单菌落进行PCR鉴定,阳性菌落接种于含有100μg/ml利福平,50μg/ml卡那霉素的YMB液体培养基,28℃,250rpm,培养过夜,再对菌液提取质粒DNA进行PCR鉴定,确定的阳性菌(LBA9402-vgb),PCR鉴定结果见图1。Inoculate Agrobacterium rhizogenes LBA9402 on YMB solid medium containing 100 μg/ml rifampicin, and culture at 28°C until a single colony grows. Pick a single colony and inoculate it in YMB liquid medium with 100 μg/ml rifampicin, at 28°C, 250 rpm, and cultivate for about 40 hours. Agrobacterium was inoculated in YMB liquid medium at an inoculation ratio of 1%, and cultivated at 28° C. and 250 rpm until the OD600 was 0.5. Inoculate the Escherichia coli pRK2013 containing the helper plasmid and the Escherichia coli carrying the intermediate vector pBI121-vgb on solid LB medium containing 50 μg/ml kanamycin, culture overnight at 37°C and 300 rpm, and when single colonies grow, pick them separately Bacteria were inoculated in liquid LB medium containing 50 μg/ml kanamycin, and cultured overnight at 37°C and 300 rpm. Inoculate the assisting bacteria and the bacteria containing the intermediate carrier in LB liquid medium at an inoculation ratio of 1%, and cultivate them at 37°C and 300 rpm until the OD600 is 0.5. After mixing the three bacteria in equal volumes, take 50 μl and inoculate them on sterile filter paper with a diameter of 2 cm, place them on YMB solid medium, and incubate at 25°C for one day. Rinse the filter paper with an appropriate amount of sterile water, collect the washed out bacterial liquid, and evenly spread it on the YMB solid medium containing 100 μg/ml rifampicin and 50 μg/ml kanamycin. After culturing at 25°C for about four days, single colony. Pick a single colony for PCR identification, inoculate positive colonies in YMB liquid medium containing 100 μg/ml rifampicin and 50 μg/ml kanamycin, cultivate overnight at 28°C, 250 rpm, and then conduct PCR identification on the plasmid DNA extracted from the bacterial liquid , the confirmed positive bacteria (LBA9402-vgb), the results of PCR identification are shown in Figure 1.
8)转vgb基因发根农杆菌LBA9402-vgb侵染黄芪无菌苗诱导毛状根8) Transgenic vgb gene Agrobacterium rhizogenes LBA9402-vgb infects Astragalus aseptic seedlings to induce hairy roots
接种发根农杆菌LBA9402-vgb在含有100μg/ml利福平和50μg/ml卡那霉素的YMB固体培养基上,28℃培养至单菌落长出。挑单菌落接种于加100μg/ml利福平和50μg/ml卡那霉素的YMB液体培养基,28℃,250rpm,培养约40hr。按1%的接种比例将农杆菌接种于YMB液体培养基中,28℃,250rpm培养过夜。加适量乙酰丁香酮至终浓度50μM,再培养一天。无菌条件下,切取黄芪无菌苗的茎和叶片,在切口处接种发根农杆菌LBA9402-vgb菌液(OD600=0.5),然后转移至MSOH固体培养基,25℃、黑暗条件下培养2天。无菌水洗涤外植体4~5次后,转移至含500mg/L Claforan的固体MSOH培养基,25℃、黑暗条件下培养诱导产生毛状根。Inoculate Agrobacterium rhizogenes LBA9402-vgb on YMB solid medium containing 100 μg/ml rifampicin and 50 μg/ml kanamycin, and culture at 28°C until a single colony grows. Pick a single colony and inoculate it in YMB liquid medium with 100 μg/ml rifampicin and 50 μg/ml kanamycin at 28° C., 250 rpm, and cultivate for about 40 hours. Agrobacterium was inoculated in YMB liquid medium at an inoculation ratio of 1%, and cultivated overnight at 28° C. and 250 rpm. Add appropriate amount of acetosyringone to a final concentration of 50 μM, and culture for another day. Under aseptic conditions, the stems and leaves of aseptic Astragalus membranaceus seedlings were cut out, and the incisions were inoculated with Agrobacterium rhizogenes LBA9402-vgb bacteria solution (OD600=0.5), then transferred to MSOH solid medium, and cultured at 25°C in the dark for 2 sky. After the explants were washed 4-5 times with sterile water, they were transferred to solid MSOH medium containing 500 mg/L Claforan, and cultured at 25°C in the dark to induce hairy roots.
9)毛状根DNA的提取9) Extraction of hairy root DNA
CTAB法提取总DNA。取500~600mg新鲜材料,液氮研细至细粉末状,然后迅速将其转入1.5ml离心管中;加入600μl 2%CTAB提取液(60℃预热),混匀,于60℃水浴放置1hr,中间温和混匀几次;12000rpm离心10min,取上清液,加等体积的水饱和酚∶氯仿∶异戊醇(25∶24∶1),混匀,4℃12000rpm离心10min,如此重复2次,至两液间无白色沉淀;取上清液,加等体积的氯仿∶异戊醇(24∶1),混匀,4℃12000rpm离心10min;取上清液加1/10 NaAc和等体积异丙醇,混匀,-20℃放置1hr;4℃5000rpm离心10min,弃上清液,沉淀用70%乙醇漂洗2次;沉淀在空气中自然干燥后,溶于30μl TE中。Total DNA was extracted by CTAB method. Take 500-600mg of fresh material, grind it into a fine powder with liquid nitrogen, then quickly transfer it to a 1.5ml centrifuge tube; add
10)黄芪毛状根vgb基因特征引物PCR鉴定10) PCR identification of characteristic primers of vgb gene in hairy roots of Astragalus membranaceus
以转vgb基因黄芪毛状根基因组DNA为模板进行PCR检测,PCR引物与条件同步骤4、6。PCR结果见图2,初步验证目的基因vgb已整合到转vgb基因黄芪毛状根中。图中M:100bp DNA Marker;1:阴性对照/黄芪无菌苗;2:阳性对照/LBA9402-vgb;3:阴性对照/未转基因黄芪毛状根;4:转vgb基因黄芪毛状根株系VHb10;5:转vgb基因黄芪毛状根株系VHb36;6:转vgb基因黄芪毛状根株系VHb52;7:转vgb基因黄芪毛状根株系VHb74The genomic DNA of the transgenic Astragalus membranaceus hairy root was used as a template for PCR detection, and the PCR primers and conditions were the same as
11)总RNA提取(一步法)11) Total RNA extraction (one-step method)
反应试剂的配制:变性液(26mM柠檬酸钠pH 4.0,0.5%十二烷基肌氨酸钠,0.125M 2-巯基乙醇,4M异硫氰酸胍);NaAc(2M,pH 4.7);酚∶氯仿∶异戊醇(25∶24∶1);70%乙醇。所有的试剂皆用0.1%DEPC水处理过的无RNase水配制,玻璃容器皆去RNase。Preparation of reaction reagents: denaturing solution (26mM sodium citrate pH 4.0, 0.5% sodium lauryl sarcosinate, 0.125M 2-mercaptoethanol, 4M guanidine isothiocyanate); NaAc (2M, pH 4.7); phenol : chloroform: isoamyl alcohol (25:24:1); 70% ethanol. All reagents are prepared with RNase-free water treated with 0.1% DEPC water, and all glass containers are RNase-free.
操作程序:取适量新鲜植物组织置于陶瓷研钵中,加入液氮快速研磨至细粉末,转移至含有650μl变性液的1.5ml离心管中混匀;加入65μl 2M NaAc(pH 4.0),反复颠倒混匀;再加入650μl酚∶氯仿∶异戊醇,混匀,冰浴15min;4℃,12000rpm,离心20min;上清转移至一新的1.5ml离心管中,加等体积异丙醇,混匀后-20℃置30min;4℃,12000rpm,离心10min沉淀RNA;弃上清液,将RNA溶于0.5ml变性液中,65℃加热尽快溶解;加入等体积酚∶氯仿∶异戊醇,混合溶液重新抽提1次,即重复前步骤;离心后,弃上清液,加75%预冷乙醇1ml,漂洗沉淀,离心同上,弃上清;空气干燥后,加20μl去离子水溶解RNA,分光光度法和凝胶电泳检测浓度和纯度,余下部分-20℃保存备用。Operating procedures: Take an appropriate amount of fresh plant tissue and place it in a ceramic mortar, add liquid nitrogen and quickly grind it to a fine powder, transfer it to a 1.5ml centrifuge tube containing 650μl denaturing solution and mix well; add 65μl 2M NaAc (pH 4.0), and invert repeatedly Mix well; then add 650 μl phenol: chloroform: isoamyl alcohol, mix well, and ice-bath for 15 min; 4°C, 12000 rpm, centrifuge for 20 min; transfer the supernatant to a new 1.5 ml centrifuge tube, add an equal volume of isopropanol, mix After homogenization, place at -20°C for 30 minutes; centrifuge at 4°C, 12,000 rpm for 10 minutes to precipitate RNA; discard the supernatant, dissolve RNA in 0.5ml denaturing solution, and heat at 65°C to dissolve as soon as possible; add an equal volume of phenol: chloroform: isoamyl alcohol, Extract the mixed solution once again, that is, repeat the previous steps; after centrifugation, discard the supernatant, add 1ml of 75% pre-cooled ethanol, rinse the precipitate, centrifuge as above, discard the supernatant; after air drying, add 20μl deionized water to dissolve the RNA , spectrophotometry and gel electrophoresis to detect the concentration and purity, and the remaining part was stored at -20°C for later use.
12)逆转录cDNA12) reverse transcription cDNA
Oligo(dT)(37.5μM)2μl,总RNA 2μg,ddH2O 10.5μl,70℃反应10min,立即置冰上,5×RT buffer 4μl,RNasin(40U/μl)0.5μl,10mM dNTPs 1μl,M-MLV逆转录酶(200U/μl)1μl,42℃反应1.5h,70℃反应10min灭活逆转录酶。Oligo(dT) (37.5μM) 2μl, total RNA 2μg, ddH 2 O 10.5μl, react at 70°C for 10min, put on ice immediately, 5×RT buffer 4μl, RNasin (40U/μl) 0.5μl, 10mM dNTPs 1μl, M -MLV reverse transcriptase (200U/μl) 1 μl, react at 42°C for 1.5h, and react at 70°C for 10min to inactivate the reverse transcriptase.
13)转vgb基因黄芪毛状根的RT-PCR13) RT-PCR of the hairy root of Astragalus transgene vgb
植物总RNA提取按步骤11进行,逆转录合成cDNA第一链按步骤12进行,总RNA加样量为3μg,PCR反应同步骤6。Extraction of plant total RNA is carried out according to step 11, and reverse transcription is carried out according to step 12 for synthesizing the first strand of cDNA.
图中M:1kb DNA Marker;1:阴性对照/黄芪无菌苗;2:阴性对照/未转基因黄芪毛状根;3:转vgb基因黄芪毛状根株系VHb36;4:转vgb基因黄芪毛状根株系VHb52;5:转vgb基因黄芪毛状根株系VHb74;6:阳性对照/LBA9402-vgbIn the figure M: 1kb DNA Marker; 1: Negative control/Astragalus membranaceus sterile seedling; 2: Negative control/Non-transgenic Astragalus hairy root; 3: VHb36 transgenic Astragalus hairy root line; 4: Vgb transgenic Astragalus hairy root Root line VHb52; 5: Transgenic vgb gene Astragalus hairy root line VHb74; 6: Positive control/LBA9402-vgb
14)转vgb基因黄芪毛状根生长量测定14) Determination of growth of hairy root of Astragalus membranaceus transgenic vgb gene
接种未转基因黄芪毛状根及转vgb基因黄芪毛状根到液体培养基中,第15天收取材料,称鲜重;冷冻干燥,称干重,计算增长倍数,结果见表1。该结果表明,转vgb基因黄芪毛状根同期生长比未转基因黄芪毛状根快,干重比未转基因黄芪毛状根增加了13%~25%。Inoculate non-transgenic Astragalus hairy roots and transgenic Astragalus hairy roots into liquid medium, collect materials on the 15th day, weigh fresh weight; freeze-dry, weigh dry weight, and calculate growth multiples. The results showed that the hairy root of astragalus transgenic with vgb gene grew faster than the hairy root of astragalus without transgene at the same period, and the dry weight increased by 13% to 25% compared with the hairy root of astragalus without transgene.
表1转vgb基因黄芪毛状根与未转基因黄芪毛状根生长测定(n=3)
15)HPLC-ELSD法测定黄芪甲苷的含量15) Determination of the content of astragaloside IV by HPLC-ELSD
样品的提取与制备Sample extraction and preparation
样品粉碎,过80目筛,每种样品称取3份,每份0.300g,加80%甲醇10ml,浸泡过夜后,80℃超声提取3次,每次30min,抽滤,合并滤液。蒸干滤液,残渣趁热加ddH2O 5ml溶解,转移至分液漏斗中,5ml水饱和正丁醇萃取3次,合并正丁醇液,0.15%NaOH洗涤1次,收集正丁醇液,蒸干正丁醇,残渣用甲醇溶解定容至2ml,摇匀后0.45μm微孔滤膜过滤,即得供试液。The sample was pulverized and passed through an 80-mesh sieve. Weighed 3 parts of each sample, each 0.300g, added 10ml of 80% methanol, soaked overnight, ultrasonically extracted 3 times at 80°C for 30min each time, filtered with suction, and combined the filtrates. Evaporate the filtrate to dryness, add ddH 2 O 5ml to dissolve the residue while hot, transfer to a separatory funnel, extract 3 times with 5ml of water-saturated n-butanol, combine the n-butanol solution, wash once with 0.15% NaOH, collect the n-butanol solution, Evaporate n-butanol to dryness, dissolve the residue with methanol and dilute to 2ml, shake well, and filter through a 0.45μm microporous membrane to obtain the test solution.
色谱条件Chromatographic conditions
色谱柱:Inertsil ODS-3(4.6*250mm,5μm);流动相:乙腈-水(35∶65);流速:1.0ml/min;柱温:室温;ELSD参数:蒸发温度:100℃,雾化温度:80℃,出口温度:60℃;载气流速:1.2ml/min。Chromatographic column: Inertsil ODS-3 (4.6*250mm, 5μm); mobile phase: acetonitrile-water (35:65); flow rate: 1.0ml/min; column temperature: room temperature; ELSD parameters: evaporation temperature: 100°C, nebulization Temperature: 80°C, outlet temperature: 60°C; carrier gas flow rate: 1.2ml/min.
标准曲线的绘制Drawing of standard curve
精密称取黄芪甲苷对照品2.31mg,用甲醇溶解并定容至2ml,0.45μm微孔滤膜过滤。依次吸取滤液1、2、5、10、15、20μl分别按上述色谱条件分析,测定峰面积。以对照品含量(μg)的对数值为横坐标(X),对照品峰面积(A)的对数值为纵坐标(Y),绘制标准曲线。并得回归方程、相关系数及线性范围为:Y=1.5856X+0.5769,r=0.9995,1.155~23.100μg。Accurately weigh 2.31 mg of astragaloside IV reference substance, dissolve it in methanol and dilute to 2 ml, and filter through a 0.45 μm microporous membrane. Sequentially draw
精密度实验Precision experiment
精密吸取黄芪甲苷对照品溶液10μl,重复5次进样测定,结果黄芪甲苷RSD=1.114%(n=5)。Precisely draw 10 μl of astragaloside IV reference substance solution, and repeat the
稳定性实验Stability test
同一样品分别在0,2,4,6,8,10,12,14,16,18,20,22,24h进样,计算含量,测定日内稳定性,结果RSD=0.79%。The same sample was injected at 0, 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, and 24 hours respectively, the content was calculated, and the intraday stability was determined. The result was RSD=0.79%.
重复性实验Repeat experiment
同种样品称取5份,每份0.300g,按3.2.3项下方法提取测定黄芪甲苷含量,计算得黄芪甲苷的平均含量17.352mg/g,RSD为2.30%。
回收率实验Recovery experiment
精密称取5份已知黄芪甲苷含量未转基因黄芪毛状根样品,每份0.300g,分别精密加入黄芪甲苷标准品,同法提取测定黄芪甲苷含量,测得平均回收率为96.72%,RSD=2.04%。Precisely weighed 5 samples of non-transgenic Astragalus hairy root samples with known astragaloside IV content, 0.300g each, and accurately added standard astragaloside IV, extracted and determined the content of astragaloside IV with the same method, and the average recovery rate was 96.72% , RSD=2.04%.
样品的测定Determination of samples
称取山西产商品膜荚黄芪药材、未转基因黄芪毛状根、转vgb基因黄芪毛状根粉末,每种3份,每份0.300g,同法制备供试液,按相同色谱条件测定供试液中黄芪甲苷的含量,外标法计算峰面积。Weigh Shanxi-produced commercial Astragalus membranaceus medicinal material, non-transgenic Astragalus hairy root, transgenic vgb gene Astragalus hairy root powder, 3 parts of each, 0.300 g per part, prepare the test solution in the same way, and determine the test solution under the same chromatographic conditions. The content of astragaloside IV in the liquid was calculated by the external standard method to calculate the peak area.
测定结果The measurement results
结果如表2所示,转vgb基因黄芪毛状根黄芪甲苷含量普遍很高,如株系36与52的黄芪甲苷含量分别为20.674mg/g和20.999mg/g,明显高于未转基因黄芪毛状根(黄芪甲苷含量为3.334mg/g)和山西产膜荚黄芪药材(黄芪甲苷含量为1.774mg/g)。The results are shown in Table 2. The content of astragaloside IV in the hairy root of Astragalus transgenic vgb gene is generally very high. For example, the content of astragaloside IV in lines 36 and 52 is 20.674 mg/g and 20.999 mg/g, which is significantly higher than that of the non-transgenic Astragalus hairy root (astragaloside Ⅳ content 3.334mg/g) and Shanxi membranous viburnum herb (astragaloside Ⅳ content 1.774mg/g).
表2转vgb基因黄芪毛状根与未转基因黄芪毛状根中黄芪甲苷含量测定(n=3)
Claims (1)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CNB2005100260264A CN100350046C (en) | 2005-05-20 | 2005-05-20 | Method for increasing content of astragalus methglycoside through exogenous gene transfer technology |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CNB2005100260264A CN100350046C (en) | 2005-05-20 | 2005-05-20 | Method for increasing content of astragalus methglycoside through exogenous gene transfer technology |
Publications (2)
Publication Number | Publication Date |
---|---|
CN1699578A CN1699578A (en) | 2005-11-23 |
CN100350046C true CN100350046C (en) | 2007-11-21 |
Family
ID=35475825
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CNB2005100260264A Expired - Fee Related CN100350046C (en) | 2005-05-20 | 2005-05-20 | Method for increasing content of astragalus methglycoside through exogenous gene transfer technology |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN100350046C (en) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101934073A (en) * | 2010-03-06 | 2011-01-05 | 吉林农业大学 | Bovine viral diarrhea virus transgenic astragalus vaccine and production method |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN100436579C (en) * | 2006-06-16 | 2008-11-26 | 中国科学院微生物研究所 | Vitreoscilla hemoglobin gene and its uses |
CN112315879B (en) * | 2020-11-13 | 2022-12-23 | 浙江颜雪化妆品有限公司 | Biological factor eyelash nourishing liquid and preparation method thereof |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1386407A (en) * | 2002-06-21 | 2002-12-25 | 武汉大学 | Application of Vitreoscilla hematoglobin gene in improving waterlogging resistance of plant |
-
2005
- 2005-05-20 CN CNB2005100260264A patent/CN100350046C/en not_active Expired - Fee Related
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1386407A (en) * | 2002-06-21 | 2002-12-25 | 武汉大学 | Application of Vitreoscilla hematoglobin gene in improving waterlogging resistance of plant |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101934073A (en) * | 2010-03-06 | 2011-01-05 | 吉林农业大学 | Bovine viral diarrhea virus transgenic astragalus vaccine and production method |
CN101934073B (en) * | 2010-03-06 | 2012-06-27 | 吉林农业大学 | Bovine viral diarrhea virus (BVDV) transgenosis astragalus mongholicus vaccine and production method |
Also Published As
Publication number | Publication date |
---|---|
CN1699578A (en) | 2005-11-23 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN100569938C (en) | Can produce the Cladosporium endogenetic fungus of trans-resveratrol | |
CN106222118B (en) | One streptomycete category actinomyces and application thereof | |
CN108865895B (en) | Paecilomyces hepiali ZJB18001 and application thereof | |
CN109295080A (en) | The use of ginseng β-arosinol synthase gene Pjβ-AS | |
CN104651319B (en) | Fusarium graminearum low-toxicity virus FgHV2/JS16 and application thereof | |
CN109081865B (en) | Moso bamboo PeVQ28 protein and its encoding gene and application | |
CN117683643A (en) | Morchella strain ZJYDJ002 with high adenosine content and application thereof | |
CN105331548B (en) | A kind of lilac mushroom strain and its liquid strain and preparation method | |
CN111233988B (en) | Eggplant potassium ion channel protein SmAKT1, and coding gene and application thereof | |
CN100350046C (en) | Method for increasing content of astragalus methglycoside through exogenous gene transfer technology | |
CN101875940B (en) | Salt-tolerant sinorhizobium meliloti NSM18 and special gene cluster thereof | |
CN112501053B (en) | Bacillus amyloliquefaciens HBNS-1, application thereof and agricultural fertilizer prepared from same | |
CN117683775B (en) | A VIGS silencing system of DpPDS gene in Chinese yam and its application | |
CN119082056A (en) | A CYP450 enzyme protein capable of catalyzing the formation of new andrographolide aglycones, its encoding gene and its application | |
CN110172411B (en) | Xylaria cruzi strain ZJ1811 and culture method and application thereof | |
CN1314804C (en) | Improvement of Astragaloside content by endogenous gene overexpression technology | |
CN102424827A (en) | Micropterus niveus delta-6 fatty acid dehydrogenase gene (Ms-delta 6-FAD) and application thereof | |
CN112358977A (en) | Alfalfa rhizobium with growth promoting effect and separation and application method thereof | |
CN103695335B (en) | Mesorhizobium huakuii and use thereof | |
CN114807166B (en) | Liriodendron transcription factor LcbHLH02399 gene and expression protein and application thereof | |
CN107099486B (en) | Bacillus amyloliquefaciens GN03 and its application | |
CN113832038B (en) | Fusarium equisetum (Fusarium equiseti) K2017-696 and application thereof | |
CN115948436A (en) | A method for rapidly identifying the gene function of Carya Carya based on TRV-VIGS technology and its application | |
CN109566271B (en) | A kind of medium for cultivating wild reticulate fungus parent species | |
CN115093972B (en) | Cordyceps militaris strain and application thereof |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
CF01 | Termination of patent right due to non-payment of annual fee | ||
CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20071121 Termination date: 20160520 |